HC Wainwright Reiterates Buy Rating for Pharvaris (NASDAQ:PHVS)

Pharvaris (NASDAQ:PHVS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $60.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 116.68% from the company’s current price.

PHVS has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Morgan Stanley lifted their price target on shares of Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Finally, Bank of America upgraded Pharvaris from an “underperform” rating to a “neutral” rating and raised their price objective for the stock from $16.00 to $27.00 in a research note on Thursday, October 9th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.56.

Pharvaris Price Performance

PHVS opened at $27.69 on Wednesday. The business has a fifty day simple moving average of $23.76 and a 200 day simple moving average of $21.51. The company has a market capitalization of $1.45 billion, a PE ratio of -8.63 and a beta of -2.80. Pharvaris has a 1 year low of $11.51 and a 1 year high of $29.80.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.08. Equities analysts anticipate that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

A number of large investors have recently modified their holdings of the business. Woodline Partners LP bought a new position in shares of Pharvaris in the 3rd quarter valued at $2,495,000. venBio Partners LLC boosted its stake in Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in Pharvaris in the third quarter valued at about $3,119,000. Polar Capital Holdings Plc bought a new position in Pharvaris in the third quarter valued at about $6,604,000. Finally, Public Employees Retirement System of Ohio raised its stake in Pharvaris by 39.3% during the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after acquiring an additional 1,769 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.